
aspirin with rivaroxaban are reasonable choices for secondary cardiovascular prevention for patients with
chronic symptomatic PAD, but the risk of bleeding and
contraindications should be taken into account when
discussing the options with the patient.137 The ESVS
antithrombotic guidelines recommend that those not
at high risk of bleeding who undergo an endovascular
intervention for lower extremity PAD may be considered
for a one to six month